Injection Log & Notifications
Track your GLP-1 injections and get timely reminders so you never miss a dose.
For Patients
Own your GLP-1 journey with personalized support
Track your medications, manage side effects, optimize nutrition, and get personalized guidance all in one app.
What is Alnu Health
Your complete GLP-1 companion
Alnu Health is a clinically-backed companion designed specifically for the GLP-1 community. Built in partnership with leading physicians and dietitians, we bring together everything you need to stay on track from medication logging and nutrition guidance to side effect monitoring and a personalized wellness coach, helping you to own your journey.
Features
Everything you need in one place
Designed around the real needs of GLP-1 community, with tools that make your journey easier.
Real-time Nutritional Insights
Get personalized caloric and macro goals with meal tracking tailored to your treatment.
Side Effect Tracking
Log and monitor common GLP-1 side effects to share with your healthcare provider.
Personalized Wellness Coach
Get contextual, historic guidance for your GLP-1 journey based on your unique health profile.
Photo, Voice & Text Tracking
Snap a photo, speak, or type to log your meals and macros whichever way works best.
Journey Graphs
Track Weight & Dose, Injections, Side Effects, and BMI over time with clear visual graphs.
Apple Health Integration
Seamlessly sync with your wearables and health data for a complete picture of your wellness.
Why Choose Alnu Health
The challenge with GLP-1 treatment
GLP-1s are transforming lives, but not without challenges. Alnu Health is built to support better outcomes.
70%
Of GLP-1 users report side effects, most commonly gastrointestinal, including nausea, vomiting, and diarrhea.[1]
50-68%
Stop GLP-1 treatment within a year before achieving meaningful health outcomes.[2-4]
2/3
Of lost weight can be regained within 1 year when GLP-1 treatment is discontinued.[5-7]
15-25%
Of total weight reduction can be lean muscle mass loss without a strength training program.[8]
References
- Rodriguez PJ, et al. JAMA Netw Open. 2025;8(1):e2457349.
- Do D, Lee T, Peasah SK, et al. JAMA Netw Open. 2024;7(5):e2413172.
- Gleason P, Urick B, Marshall L, et al. Prime Therapeutics real-world GLP-1 study. 2024.
- Gleason PP, Urick BY, Marshall LZ, et al. J Manag Care Spec Pharm. 2024;30(8):860-867.
- Aronne L, Sattar N, Horn DB, et al. JAMA. 2024;331(1):38-48.
- Rubino D, Abrahamsson N, Davies M, et al. JAMA. 2021;325(14):1414-1425.
- Wilding JPH, Batterham RL, Davies M, et al. Diabetes Obes Metab. 2022;24(8):1553-1564.
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Obesity (Silver Spring). 2025.